正在加载视频...
视频加载失败
NewLimit CEO Jacob Kimmel explains the clinical trial bottleneck AI can't fix: biology has irreducible latency "It's unlikely we're gonna see rapid expedition of clinical trials because a lot of the periods of time can't be expedited based on the biological primitives. In computer science you often have a... show more
50,797 次观看 • 13 天前 •via X (Twitter)
11 条评论

@jacobkimmel What we really need is clinical trial abundance

@jacobkimmel Just say slow

@jacobkimmel does newlimit's model actually move the 10 percent number or just pick better candidates going into the same slow pipe

@jacobkimmel Very much matches what I dicsussed with Rico from Retro Bio last month

@jacobkimmel AI may not eliminate biology’s inherent latency, but improving clinical success rates could transform drug development. Doubling success from 10% to 20% would be a massive leap in both impact and economics.

@jacobkimmel True

@jacobkimmel I like the way this is explained. Moderna just reported out its data for the mRNA vaccine in skin cancer based on 5 year survival. So right there you have 5 year latency for a cancer cure claim.

The bandwidth/latency framing is exactly right, and it has a financial twin: cost of capital compounds over a fixed 10-year clock you can't shorten, so the only lever left is raising the hit rate. Doubling success from 10% to 20% doesn't just halve cost per approval — it changes what a portfolio is worth at every discount rate.

@jacobkimmel Trials is the only thing that matters in biotech. They make it brake companies. It’s the end all be all. They take forever and they cost a ton. You cannot work around them. The trials is the drugs.

@jacobkimmel Brilliant insight AI improving trial success rates could revolutionize medicine forever🧬🔥

Our map of human biology is built on sparse, biased data, shallow clinical data and a literature full of contradiction, and which conflates correlation with causation. The bottleneck might not be AI, but actually understanding how human biology moves when we perturb it in non-consensus ways.
